东曜药业-B今日盘中股价大幅上涨11.02%，市场表现强劲。
消息面上，此次股价异动主要源于药明合联对其发起的现金要约收购已正式生效。据悉，药明合联已取得东曜药业60%股权的有效接纳，标志着此次战略整合进入新阶段。市场分析认为，此次整合是基于双方对ADC（抗体偶联药物）及生物偶联药物领域巨大发展潜力的共同看好，也是对东曜药业在生产设施、技术经验及质量体系等方面优势的认可。
此次强强联合被视作典范，预计将显著增强公司的综合服务能力和全球市场竞争力。值得注意的是，协同效应已初步显现，药明合联已将部分客户订单转至东曜药业，并获得客户积极反馈，这进一步印证了市场对东曜药业ADC CDMO技术及执行效率的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.